3. Taher A, Isma’eel H, Cappellini MD. Thalassemia intermedia: revisited. Blood Cells Mol Dis 2006;37:12-20.
4. Huehns ER, Dance N, Beaven GH, Hechter F, Motulsky AG. Human embryonic hemoglobins. Cold Spring Harb Symp Quant Biol 1964;29:327-31.
5. Vilegas A, Ropero P, González FA, Anguita E, Espinós D. The thalassemia syndromes: molecular characterization in the Spanish population. Hemoglobin 2001;25:273-83.
6. Nadkarni A, Gorakshakar AC, Lu CY, et al. Molecular pathogenesis and clinical variability of beta-thalassemia syndromes among Indians. Am J Hematol 2001;68:75-80.
7. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med 2005;353:1135-46.
8. Schechter AN. Hemoglobin research and the origins of molecular medicine. Blood 2008;112:3927-38.
9. Nagar R, Sinha S, Raman R. Genotype-phenotype correlation and report of novel mutations in β-globin gene in thalassemia patients. Blood Cells Mol Dis 2015;55:10-4.

**Comparison of the acute erythropoietic capacities of erythropoietin and U-74389G in terms of hemoglobin levels**

**TO THE EDITOR:** This study compared the erythropoietic capacities of erythropoietin (EPO) and antioxidant drug U-74389G based on the findings of 2 preliminary studies. Hemoglobin augmentation was evaluated using a hypoxia reoxygenation (HR) protocol in an animal model. Hemoglobin levels were evaluated at the 60th reoxygenation minute (for groups A, C, and E) and at the 120th reoxygenation minute (for groups B, D, and F) in 60 rats. Groups A and B were administered no drugs, groups C and D were administered EPO, and groups E and F were administered U-74389G. The first preliminary study of EPO did not show a significant increase in hemoglobin levels. However, the second preliminary study of U-74389G showed a significant increase in hemoglobin levels by 2.5±1.3% (P=0.0423). These 2 studies were co-evaluated because they were conducted in the same experimental setting. In non-deficient EPO rats, U-74389G demonstrated an approximately 2-times higher erythropoietic potency than EPO (P=0.0000). This is because the anti-oxidant capacity of U-74389G increased the acute erythropoietic potency.

A previous study claims that U-74389G harbors a remarkable acute erythropoietic capacity [1]. U-74389G is a novel antioxidant factor and has shown tissue protective effects in tissue hypoxia and reoxygenation (HR) experiments. U-74389G, also known as 21-[4-(2.6-di-1-pyrimidinyl-4-pyrimidinyl)-1-piperazinyl]-pregna-1,4,9(11)-triene-3,20-dione maleate salt, prevents both arachidonic acid-induced and iron-dependent lipid peroxidation. It has been shown to protect against HR injury in animal heart, liver, and kidney models. These membrane-associating anti-oxidants are particularly effective in preventing permeability changes in brain microvascular endothelial cells monolayers. Lazaroids, or 21-aminosteroids, a novel series of glucocorticoid compounds, scavenge free radicals. U-74389G is one of the 132 similar lazaroid compounds. It has a molecular weight of 726.90406 g/mol and demonstrates selective action on the vascular endothelium with vitamin E-like properties.

However, the erythropoietic capacity of U-74389G appears more comprehensible when compared with that of a standard known drug. One such well-studied drug, where-in erythropoietic capacity was confirmed (P=0.3984), is EPO. Indeed, EPO has been implicated in over 29,946 known biomedical studies. Among these studies, 30.65% concern tissue HR experiments. However, only a few reports that were found to be related with this study did not completely address the specific matter of antioxidant factors. The aim of this experimental work was to compare the acute erythropoietic capacities of U-74389G and EPO in a non-deficient EPO rat model using an HR protocol. Their effects were assessed on the basis of increase in hemoglobin levels.

The veterinarian licenses for the research were provided under the 3693/12-11-2010 & 14/10-1-2012 decisions. The institute and place of experiment are mentioned in the related references [1, 2]. The experimental protocol, which involved Albino female Wistar rats, adhered to the ethical rules of the relevant organization. For 7 days pre-experimentally, the rats were placed under normal housing and fed ad libitum in the laboratory. Continuous intra-experimental general anesthesia, oxygen supply, electrocardiography, acidometry, and post-experimental euthanasia were provided. Subsequently, 16-18-week-old rats were randomly divided into 6 groups (N=10) according to the HR protocol: hypoxia for 45 minutes followed by reoxygenation for 60 minutes (group A); hypoxia for 45 minutes followed by reoxygenation for 120 minutes (group B); hypoxia for 45 minutes followed by immediate intravenous (IV) EPO administration and reoxygenation for 60 minutes (group C); hypoxia for 45 minutes followed by immediate IV EPO administration and reoxygenation for 120 minutes (group D); hypoxia for 45 minutes followed by immediate U-74389G IV administration and reoxygenation for 60 minutes (group E); hypoxia for 45 minutes followed by immediate U-74389G IV administration and reoxygenation for 120 minutes (group F). The dose height selection criteria for EPO and U-74389G were assessed in preliminary studies as 10 mg/kg body mass for both drugs.

Hypoxia was induced by laparotomic clamping of the inferior aorta over the renal arteries with forceps for 45 minutes. Clamp removal restored the inferior aorta patency and reoxygenation. After exclusion of the blood flow, the HR protocol was followed as described above for each experimental group. The drugs were administered at the time...
of reperfusion through the inferior vena cava catheter. The hemoglobin levels were determined at the 60th minute of reoxygenation (for groups A, C, and E) and the 120th minute of reoxygenation (for groups B, D, and F).

Table 1 presents the percent (%) augmentation influence of both drugs according to reoxygenation time. Chi-square tests were applied using the ratios, which yielded the percent (%) results per endpoint (Table 2). The statistical analysis was performed using Stata 6.0 (StataCorp LP, Texas, USA). The chi-square tests revealed that U-74389G favored erythropoiesis at 1 hour by 1.268689-fold (1.26728–1.2701) compared with EPO by 1.839035-fold (1.836445–1.84163) at 1.5 hour, by 13.1658-fold (13.11695–13.21483) at 2 hour, by 1.252422-fold (1.250726–1.25412) without drugs, and by 1.94889-fold (1.945431–1.952355) when all variables were considered (P=0.0000).

The only available study investigating the effect of U-74389G on increasing hemoglobin levels was a preliminary one [1]. Himmelfarb et al. [3] reported an increase in the markers of oxidative stress (OS), such as F2 isoprostanes and isofurans, with decreased EPO responsiveness; however, they failed to confirm the hypothesis that oral antioxidant therapy administered over 6 months would decrease the levels of OS biomarkers and improve erythropoietic response in patients receiving maintenance hemodialysis therapy. Jilani and Iqbal [4] observed that the prevention of polyunsaturated fatty acid oxidation in red blood cell membranes reduced the fragility of erythrocytes, inhibited premature erythroyctolysis, increased the number of colony forming units of erythroid precursors, enhanced erythropoiesis, and improved blood hemoglobin levels. Martinez Mendel et al. [5] reported reduced free heme pool-inducing heme oxygenase levels and δ–aminolevulinate synthase activity and a low rate of holo/apo tryptophan pyrrolase activity. Prats et al. [6] suggested that impaired erythrocyte antioxidant defense and OS may play a role in the development of anemia in chronic kidney disease and promote erythropoiesis-stimulating agent resistance because of lower extracellular glutathione peroxidase activity in non-responders to erythropoiesis-stimulating agents. Martinez Mdel et al. [7] reported, with regard to the heme biosynthetic pathway, that a decrease in δ–aminolevulinate synthase activity exerts antioxidant-protective effects on OS, thus decreasing lipid peroxidation and the activity of some antioxidant enzymes. Goldstein and Harber [8] demonstrated lipid peroxidation as follows: (a) the formation of 2-thiobarbituric acid reactants; (b) the presence of conjugated diene bonds in red cell lipid; (c) the selective loss of unsaturated fatty acids proportional to the number of carbon-carbon double bonds. The formation of peroxides leads to oxygen-dependent colloid osmotic hemolysis, before which there is a decline in cell membrane sulfhydryl groups and a loss in activity of the cell membrane enzyme acetylcholinesterase, which is accelerated with the addition of linoleic acid.

Another study confirmed the short-term or long-term erythropoietic effect of various EPO preparations in 55 IR laboratory or clinical biomedical studies on human individuals or animals [2]. Arslantaş et al. [9] reported increasing hemoglobin levels after subsequent intraperitoneal 400 μ/kg/day EPO injections following a wound formation, administered once daily for up to 10 days after operation and accompanied by a transient surge in healing on day 5 in Sprague–Dawley rats. Khodosovskii and Zinchuk [10] showed that hepatic 30-minute ischemia/120-minute reperfusion (IR) led to significant decreases in the hemoglobin oxygen affinity. Recombinant human erythropoietin (rHEPO) administered at 100 IU/kg aggravates the decreasing hemoglobin oxygen affinity during IR. rHEPO infusion (id dose 1,000 IU/kg) shifts the oxyhemoglobin dissociative curve to the left. Kalantzi et al. [11] observed an early peak in serum EPO levels that occurred within 2 days after renal transplantation and a late peak, between weeks 2 and 4, which resulted in increased blood hemoglobin levels. Normal hemoglobin values were restored approximately 3 months after successful renal transplantation. Hernández-Navarrete et al. [12] observed stable hemoglobin levels at 24 months posttransplant after pretransplant EPO and iron dextran administration with the use of an intraoperative cell saver in 3 kidney transplant patients. Zabaneh et al. [13] reported that most peritoneal dialysis patients with chronic kidney disease maintained hemoglobin levels between 10 g/dL and 12 g/dL (63.0%) and within ±1.0 g/dL.

### Table 1. The percent (%) augmentation influence of both drugs versus reoxygenation time.

| Drug           | Augmentation | ±SD  | Reoxygenation time | P   |
|----------------|--------------|------|--------------------|-----|
| U-74389G       | +5.20%       | ±2.83%| 1 hr               | 0.0925 |
| Erythropoietin | +4.09%       | ±3.97%| 1 hr               | 0.3350 |
| U-74389G       | +3.95%       | ±2.10%| 1.5 hr             | 0.0604 |
| Erythropoietin | +2.15%       | ±2.63%| 1.5 hr             | 0.4527 |
| U-74389G       | +2.71%       | ±3.19%| 2 hr               | 0.3544 |
| Erythropoietin | +0.20%       | ±3.71%| 2 hr               | 0.9584 |
| U-74389G       | +3.40%       | ±2.13%| Reoxygenation time | 0.1285 |
| Erythropoietin | +2.71%       | ±2.62%| Reoxygenation time | 0.3457 |
| U-74389G       | +2.56%       | ±1.25%| Interaction        | 0.0423 |
| Erythropoietin | +1.31%       | ±1.59%| Interaction        | 0.3984 |

### Table 2. U-74389G/erythropoietin efficacy ratios according to hemoglobin levels augmentation after chi-square tests application.

| Odds ratio | 95% Confidence interval | P   | Endpoint |
|------------|-------------------------|-----|----------|
| +1.26889   | 1.26728–1.2701           | 0.0000 | 1 hr     |
| +1.839035  | 1.836445–1.84163         | 0.0000 | 1.5 hr   |
| +13.1658   | 13.11695–13.21483        | 0.0000 | 2 hr     |
| +1.252422  | 1.250726–1.25412         | 0.0000 | Reperfusion time |
| +1.94889   | 1.945431–1.952355        | 0.0000 | Interaction |
of the baseline level (60.9%) during the 25-week evaluation period. The mean hemoglobin value during the evaluation period was 11.3±1.07 g/dL and the mean change from baseline level (60.9%) during the 25-week evaluation period was 11.3±1.07 g/dL (95% confidence limit; -0.24–0.44 g/dL). The median weekly epoetin α dose at baseline was 96.0 U/kg. Bartnicki et al. [14] claimed that EPO involves a trend enhanced with time in non-deficient EPO animals. This trend was approximately 2-fold of that with EPO (P=0.0000; Table 3), [15].

### Table 3. A U-74389G/erythropoietin efficacies ratios meta-analysis on 9 hematologic variables (7 variables with balancing efficacies and 2 variables with opposite efficacies) [15].

| Endpoint variable                  | 1 hr   | P       | 1.5 hr | P     | 2 hr   | P     | Reperfusion time | P     | Interaction | P     |
|-----------------------------------|--------|---------|--------|-------|--------|-------|------------------|-------|-------------|-------|
| WBC                               | 0.957451 | 0.3782 | 1.396122 | 0.0000 | 1.918237 | 0.0000 | 1.71622 | 0.0000 | 1.601887 | 0.0000 |
| Hematocrit                         | 38.424 | 0.0000 | 9.076658 | 0.0000 | 6.222898 | 0.0000 | 1.001356 | 0.2184 | 12.66419 | 0.0000 |
| Hemoglobin                         | 1.268689 | 0.0000 | 1.839035 | 0.0000 | 13.1658 | 0.0000 | 1.252422 | 0.0000 | 1.94889 | 0.0000 |
| RBC count                          | 0.961059 | 0.0000 | 1.733395 | 0.0000 | 6.519657 | 0.0000 | 1.039524 | 0.0000 | 1.309673 | 0.0000 |
| Platelet count                     | 2.42839 | 0.0000 | 6.00238 | 0.0000 | 6.1333429 | 0.0000 | 3.939027 | 0.0000 | 37.62979 | 0.0000 |
| Platelet DW                        | 0.6940233 | 0.0000 | 1.319118 | 0.0000 | 2.206972 | 0.0000 | 2.2484006 | 0.0000 | 2.458888 | 0.0000 |
| Creatinine                         | 168.9034 | 0.0000 | 4.872332 | 0.0000 | 3.039572 | 0.0000 | 1.0262016 | 0.0000 | 5.005523 | 0.0000 |
| Mean                               | 3.86005598 | 0.0540 | 2.85823064 | 0.0000 | 4.57821524 | 0.0000 | 1.53777117 | 0.0312 | 4.22373897 | 0.0000 |
| Mean corpuscular hemoglobin        | −0.2774225 | 0.0000 | −0.5504722 | 0.0000 | −0.8524233 | 0.0000 | +3.044774 | 0.0000 | −0.7793243 | 0.0000 |
| Platelet crit                      | −0.2312044 | 0.0000 | −0.6719365 | 0.0000 | −1.330756 | 0.0000 | 5.620077 | 0.0000 | −0.9771515 | 0.0000 |
| Mean                               | −0.2532076 | 0.0000 | −0.6081795 | 0.0000 | −1.0649544 | 0.0000 | 4.1366488 | 0.0000 | −0.8726499 | 0.0000 |

**Authors’ Disclosures of Potential Conflicts of Interest**

No potential conflicts of interest relevant to this article were reported.

**REFERENCES**

1. Tsompos C, Panoulis C, Toutouzas K, Zografos G, Papalois A. The effect of the antioxidant drug “U-74389G” on haemoglobin levels following a hypoxemia/ re-oxygenation protocol in rats. J Crit Care Med 2015;1:102-6.
2. Tsompos C, Panoulis C, Toutouzas K, Zografos G, Papalois A. The short-term effect of erythropoietin on hemoglobin during ischemia reperfusion injury in rats. Fiziologija 2013;23:26-32.
3. Himmelfarb J, Ikizler TA, Ellis C, et al. Provision of antioxidant therapy in hemodialysis (PATH): a randomized clinical trial. J Am Soc Nephrol 2014;25:623-33.
4. Jilani T, Iqbal MP. Does vitamin E have a role in treatment and prevention of anemia? Pak J Pharm Sci 2011;24:237-42.
5. Martinez Mdel C, Afonso SG, Meiss RP, Buzaleh AM, Batlle A. Hepatic damage and oxidative stress induced by Griseofulvin in mice. Cell Mol Biol (Noisy-le-grand) 2009;55:127-39.
6. Prats M, Font R, Garcia C, et al. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients. Clin Nephrol 2014; 81:419-26.
7. Martinez Mdel C, Afonso SG, Buzaleh AM, Batlle A. Protective action of antioxidants on hepatic damage induced by griseofulvin. ScientificWorldJournal 2014;2014:982358.
8. Goldstein BD, Harber LC. Erythropoietic protoporphyria: lipid peroxidation and red cell membrane damage associated with photohemolysis. J Clin Invest 1972;51:892-902.
9. Arslantaş MK, Arslantaş R, Tozan EN. Effects of systemic erythropoietin on ischemic wound healing in rats. Ostomy Wound Care Res 2017;52:316-39.
TO THE EDITOR: Corticosteroids have been widely used in patients with paroxysmal nocturnal hemoglobinuria (PNH), based on the notion that administration may ameliorate hemolysis. However, there is no strong evidence of clinical benefit in the inhibition of complement-mediated hemolysis associated with corticosteroids. The short-term use of prednisolone (Pd) may be beneficial in some situations, but long-term use is generally not recommended because of concerns regarding complications [1, 2]. Eculizumab is a humanized monoclonal antibody that blocks terminal complement by binding to C5. This antibody is a standard therapeutic modality for PNH and has altered the natural history of the disease [3, 4]. A subpopulation of patients placed on eculizumab, however, still require red blood cell (RBC) transfusion [5], and standard salvage therapies for these patients have yet to be determined. We retrospectively analyzed the therapeutic effects of low-dose Pd in patients with PNH who show inadequate responses to eculizumab treatment.

Seven patients were treated with eculizumab between February 2012 and April 2016 at Chungnam National University Hospital. All patients were men and the median duration of the disease was 19.1 years (range, 5.1–24.5 yr). At the time of analysis, all patients were still taking eculizumab, and the median duration of eculizumab treatment was 36.3 months (range, 6.9–39.1 mo). After 6 months of eculizumab treatment, all patients showed improvement of anemia and hemolysis. Four (57.1%) patients showed an optimal response, one (14.2%) showed a major response and 2 (28.5%) showed a partial response, according to a modification of a previously reported stratification [6, 7].

During the first 12 months of eculizumab treatment, 4 patients no longer required RBC transfusion; however, 3 patients continued to require transfusion, although the transfusion requirements were reduced. Low-dose Pd (5 mg/day) was additionally administered to these 3 patients.

Of the 3 patients requiring transfusion, patient 1 was previously diagnosed with aplastic anemia (AA) and patient 2 had concurrent chronic kidney disease. At the time of initiation of low-dose Pd therapy, the hemoglobin (Hb) levels were 8.9, 8.9, and 8.3 g/dL, respectively, and the lactate dehydrogenase (LDH) levels were 418, 655, and 1,069 IU/L, respectively, in these 3 patients. The direct Coombs test was positive in all 3 patients, and the CH50 levels after 6 months of eculizumab treatment were 4.4 U/mL, <2.0 U/mL, and 20.9 U/mL, respectively (<2.0 U/mL, 10.3 U/mL, 5.4 U/mL, and 5.2 U/mL, respectively, in patients with optimal response). Low-dose Pd (5 mg/day) was administered to these 3 patients, and the Hb levels gradually increased over 12 months. The LDH levels were maintained or modestly decreased. Patient 3 experienced 2 infection episodes (upper respiratory infection with fever and tenosynovitis of the right wrist). Decreases in the Hb level and increases in the LDH level were observed during each event. During the 12 months of additional low-dose Pd therapy, the requirements for RBC transfusion in these 3 patients were modestly decreased. While a total of 26 packs of RBC transfusion were needed before Pd therapy, only 10 packs were needed after 12 months, indicating that low-dose Pd induced a favorable effect of about 60% reduction in RBC transfusion requirements (Table 1). There were no severe adverse events related to low-dose Pd therapy. Patient 1 experienced a mild upper respiratory infection after 1 month of Pd, and this spontaneously resolved. As mentioned above, patient 3 experienced 2 mild infections that were manageable with oral antibiotics.

In the present analysis, 3 of 7 patients required RBC transfusion, even after long-term eculizumab treatment. Inadequate hematologic benefit in some patients may be related to complement protein C3. Because eculizumab inhibits the terminal complement cascade and has no effect on proximal components, C3 and its fragments accumulate on RBCs in PNH patients. This phenomenon leads to destruction of RBCs in the spleen and liver. As a result, extravascular hemolysis is increased and might result in dependence on RBC transfusion [7]. Considering such a mecha-